Correspondence 0001104659-23-017722 from Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502) (QNRX)
Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502)
Date: Feb. 9, 2023 · CIK: 0001671502 · Accession: 0001104659-23-017722
AI Filing Summary & Sentiment
File numbers found in text: 333-269543
Show Raw Text
CORRESP
1
filename1.htm
Quoin Pharmaceuticals Ltd.
42127 Pleasant Forest Court
Ashburn, VA 20148-7349
February 9, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
RE: Quoin Pharmaceuticals Ltd.
Registration Statement on
Form S-1
Registration
No. 333-269543
Ladies and Gentlemen:
Quoin Pharmaceuticals Ltd.
(the “Company”) hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration
of the effective date of the above-referenced Registration Statement, as amended, so that such Registration Statement, as amended, will
become effective at 4:00 p.m.., Eastern Time, on Friday, February 10, 2023, or as soon thereafter as practicable.
[Signature Page Follows]
Very truly yours,
QUOIN PHARMACEUTICALS LTD.
By:
/s/ Dr. Michael Myers
Name: Dr. Michael Myers
Title: Chief Executive Officer